Nancy Peacock, MD, of Tennessee Oncology, and
Breast Cancer Survivor Julie Megee Discuss Supportive Care Options,
Tamoxifen/Soltamox Therapy Adherence, Patient Education
Balancing Act Breast Cancer Segment Airs on
Lifetime Television on Oct. 14 and 21
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive
care pharmaceutical company dedicated to providing health care
professionals a synergistic portfolio of medicines to help cancer
patients adhere to their therapy and manage side effects arising
from their cancer treatment, is sponsoring a breast cancer patient
education segment on The Balancing Act® airing on Lifetime
Television. The segment, which airs Oct. 14 and 21 at 7 a.m. EDT
during Breast Cancer Awareness Month, features Nancy Peacock, MD,
Tennessee Oncology medical oncologist and breast cancer specialist
at St. Thomas Midtown Hospital in Nashville, Tenn., and breast
cancer survivor Julie Megee of Wrentham, Mass.
Nancy Peacock, MD, and breast cancer
survivor, Julie Megee from Wrentham, Mass., join The Balancing
Act(R) host Danielle Knox in studio and discuss important oncology
supportive care issues (Photo: Business Wire)
Dr. Peacock and Ms. Megee join The Balancing Act® host Danielle
Knox in studio and discuss important oncology supportive care
issues, including patient compliance to tamoxifen, and how
Soltamox® (tamoxifen citrate) oral solution may help benefit
compliance. The segment also touches on side effects of cancer
treatment, including skin burns and oral mucositis caused by
radiation treatment and chemotherapy. DARA markets Gelclair®, an
oral rinse gel for relief of oral mucositis pain, and Bionect®, a
topical treatment for skin irritation and burns, in the US
oncology/radiology markets. Dr. Peacock and Julie also discuss the
important role of patient educational resources such as
Breastcancer.org.
“We are pleased to partner with The Balancing Act® to produce
this educational segment about breast cancer treatment and support,
and appreciate The Balancing Act’s commitment to breast cancer
education and programming during Breast Cancer Awareness Month,”
said David J. Drutz, MD, DARA's chief executive officer and chief
medical officer. “We are grateful to Dr. Peacock and Ms. Megee for
sharing their experiences on national television, so that others
may learn from their insights and knowledge.”
One issue that ties Dr. Peacock and Ms. Megee together is
tamoxifen therapy. According to recently published National
Comprehensive Cancer Network (NCCN) Guidelines (Version 3.2013),
tamoxifen is the most firmly established adjuvant endocrine therapy
for both premenopausal and postmenopausal women with estrogen
receptor-positive breast cancer. Tamoxifen is usually administered
as 20mg daily for five years. The American Society of Clinical
Oncology (ASCO) Clinical Practice Guidelines published on July 8,
2013, recommends that in women at increased risk of breast cancer
age 35 or older, tamoxifen prophylaxis (20mg per day for five
years) should be discussed as an option to reduce the risk of
estrogen receptor (ER) positive breast cancer. Soltamox® (tamoxifen
citrate) oral solution is bioequivalent to tamoxifen and is
prescribed for the same indications. Please see Soltamox Important
Safety Information and the Black Box Warning at the end of this
press release. For additional information and a copy of the
complete Prescribing Information visit www.soltamox.com.
Megee, a 41-year-old mother of two and owner of Perceptions Hair
Studio in Norton, Mass., asked her physician about the option of
using Soltamox® instead of tamoxifen tablets because of her
long-standing aversion to pills. Dr. Peacock recommends physicians
discuss the importance of adherence to tamoxifen/Soltamox® therapy
in detail because many patients do not realize its significance in
preventing the recurrence of breast cancer. Studies show between 30
and 70 percent of patients who are prescribed tamoxifen as adjuvant
therapy fail to complete their prescribed course of treatment which
can increase the risk of breast cancer recurrence.
Education and support from family, friends and other women who
have battled breast cancer play key roles in patients’ lives, said
both Dr. Peacock and Ms. Megee. Both discuss the value and
importance of online educational resources and communities like
Breastcancer.org.
“We are thrilled that Dr. Peacock and Ms. Megee turn to online
resources like Breastcancer.org as we are dedicated to providing
the most reliable, complete, and up-to-date information about
breast cancer to help women and their loved ones make informed
decisions for their lives,” Rita Lusen, vice president of corporate
partnerships and marketing of Breastcancer.org. “Thank you and
congratulations to DARA and The Balancing Act® on producing this
timely educational segment about breast cancer and supportive
care.”
About DARA BioSciences
DARA BioSciences Inc. is an oncology supportive care
pharmaceutical company dedicated to providing healthcare
professionals a synergistic portfolio of medicines to help cancer
patients adhere to their therapy and manage side effects arising
from their cancer treatment.
DARA holds exclusive U.S. marketing rights to Soltamox®
(tamoxifen citrate) oral solution, the only liquid form of
tamoxifen, used for the treatment and prevention of breast cancer.
Soltamox® offers a choice to patients who prefer or need a liquid
form of tamoxifen. Gelclair® is an alcohol-free bioadherent oral
rinse gel for rapid and effective relief of pain associated with
oral mucositis caused by chemotherapy and radiation treatment. DARA
licensed the U.S. rights to Soltamox® from UK-based Rosemont
Pharmaceuticals, Ltd., and Gelclair® from the Helsinn Group in
Switzerland. Under an agreement with Innocutis, DARA also markets
Bionect (hyaluronic acid sodium salt, 0.2%), a topical treatment
for skin irritation and burns associated with radiation therapy, in
US oncology/radiology markets.
DARA is focused on expanding its portfolio of oncology
supportive care products in the US, via in-licensing and/or
partnering of complementary late-stage and approved products. In
addition, the company wishes to identify a strategic partner for
the clinical development of KRN5500, currently in Phase 2 for the
treatment of chronic, treatment refractory, chemotherapy induced
peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the
treatment of CCIPN.
For additional information about Gelclair and a copy of the full
Prescribing Information please visit www.gelclair.com. For
additional information about Bionect and a copy of the full
Prescribing Information please visit www.bionect.com
About Breastcancer.org
Breastcancer.org is the #1 online resource for breast health and
breast cancer information and support, with more than 6,000 pages
of expert-reviewed information and a robust, dynamic peer support
community. A nonprofit organization, Breastcancer.org receives more
than 12 million visits each year.
About The Balancing
Act® on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower
women in all aspects of their lives. The mission at The Balancing
Act® is simple -- the show strives to help today’s modern woman
balance it all by bringing them exceptional solutions to everyday
problems. Entertaining, educational and trusted by women, viewers
can watch America’s premier morning show The Balancing Act® weekday
mornings on Lifetime television at 7 am (ET/PT).
For additional information or to view a segment visit
www.thebalancingact.com
IMPORTANT SAFETY
INFORMATION
Tamoxifen citrate is contraindicated in patients with known
hypersensitivity and also in women who require concomitant
coumarin-type anticoagulant therapy or in women with a history of
deep vein thrombosis or pulmonary embolus. As with other additive
hormonal therapy (estrogens and androgens), hypercalcemia has been
reported in some breast cancer patients with bone metastases within
a few weeks of starting treatment with tamoxifen. If hypercalcemia
does occur, appropriate measures should be taken and, if severe,
tamoxifen should be discontinued. There is evidence of an increased
incidence of thromboembolic events, including deep vein thrombosis
and pulmonary embolism, during tamoxifen therapy. When tamoxifen is
coadministered with chemotherapy, there may be a further increase
in the incidence of thromboembolic effects. Adverse reactions to
tamoxifen are relatively mild and rarely severe enough to require
discontinuation of treatment in breast cancer patients.
WARNING
In Women with Ductal Carcinoma in Situ (DCIS) and Women at High
Risk for Breast Cancer Serious and life-threatening events were
associated with tamoxifen in the risk reduction setting (women at
high risk for cancer and women with DCIS) include uterine
malignancies, stroke and pulmonary embolism. (see CLINICAL
PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer
Incidence In High Risk Women). Health care providers should discuss
the potential benefits versus the potential risks of these serious
events with women at high risk of breast cancer and women with DCIS
considering tamoxifen to reduce their risk of developing breast
cancer. The benefits of tamoxifen outweigh its risks in women
already diagnosed with breast cancer.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-855-273 0468
Safe Harbor Statement
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements
are subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the
expectations described in these forward-looking statements are set
forth under the caption “Risk Factors” in DARA’s most recent Annual
Report on Form 10-K, filed with the SEC on March 28, 2013. Those
factors include risks and uncertainties relating to DARA's ability
to timely commercialize and generate revenues or profits from
Bionect®, Soltamox®, Gelclair® or other products given that DARA
only recently hired its initial sales force and DARA's lack of
history as a revenue-generating company, FDA and other regulatory
risks relating to DARA's ability to market Bionect, Soltamox,
Gelclair or other products in the U.S. or elsewhere, DARA's ability
to develop and bring new products to market as anticipated, DARA's
current cash position and its need to raise additional capital in
order to be able to continue to fund its operations, the current
regulatory environment in which DARA develops and sells its
products, the market acceptance of those products, dependence on
partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors
identified in the documents DARA has filed, or will file, with the
Securities and Exchange Commission ("SEC"). Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in DARA's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are
based. DARA BioSciences and the DARA logo are trademarks of DARA
BioSciences, Inc.
Keywords: Balancing Act, DARA BioSciences, tamoxifen, liquid
tamoxifen, Soltamox, ductal carcinoma in situ, node-positive breast
cancer, Tennessee Oncology, St. Thomas Midtown Hospital, breast
cancer, estrogen receptor positive, liquid formulation.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131004005130/en/
Media Contacts:LaVoie GroupDavid Connolly or
Samantha Stenbeck,
617-374-8800dconnolly@lavoiegroup.comsstenbeck@lavoiegroup.comorCorporate
Contact:DARA BioSciencesJenene Thomas,
908-938-1475jthomas@darabio.com
(MM) (NASDAQ:DARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:DARA)
Historical Stock Chart
From Jul 2023 to Jul 2024